Speaker Profile
Ph.D., AVP, Amgen
Biography
Dr. Janet Jin is an accomplished leader in precision medicine with nearly 20 years of experience across the pharmaceutical and diagnostics industries. She leads a global multidisciplinary organization focused on advancing biomarker-driven drug development, with expertise spanning clinical diagnostics, imaging, translational pathology, and computational biology across therapeutic areas.
Dr. Jin provides strategic leadership in the development and execution of patient selection, pharmacodynamic, and target engagement biomarker strategies, reverse translation, and the integration of innovative biomarker technology platforms to accelerate drug development and enhance clinical decision-making. She collaborates across cross-functional teams and external partnerships to ensure precision medicine strategies are effectively implemented and aligned with global regulatory requirements.
Earlier in her career, Dr. Jin led oncology assay development efforts advancing next-generation sequencing (NGS)-based liquid biopsy platforms for biomarker discovery and minimal residual disease assessment, contributing to the broader adoption of liquid biopsy technologies and their application in precision oncology.
AI and Data Sciences Showcase:
AtaraxisAI
Session Abstract – PMWC 2027 Silicon Valley
Track Chair:
Emre Baser, AstraZeneca
PMWC Award Ceremony
• Max Diehn, Stanford (Pioneer)
• Sarah-Jane Dawson, Peter MacCallum Cancer Centre / University of Melbourne (Luminary)
Featured Speakers
• Max Diehn, Stanford
• Sarah-Jane Dawson, University of Melbourne
• Phil Febbo, Veracyte
• Ash Alizadeh, Stanford
• Adrian Lee, University of Pittsburgh
• Emre Baser, AstraZeneca
• Keith Flaherty, Mass General
• Thomas Powles, Barts Cancer Institute
Early-Stage Cancer: Can MRD Decide Who Needs More Treatment?
When ctDNA should change escalation, de-escalation, and surveillance.
Advanced Cancer Monitoring
Detecting response, resistance, and relapse early enough to switch therapy.
From Blood to Drug
Liquid biopsy for therapy selection and matching patients to the right intervention.
Integrating Tissue, Liquid & Imaging Biomarkers
How multimodal monitoring should work in real oncology care.
MRD as a Surrogate Endpoint
The promise and hazards of using MRD to accelerate drug approval.
PMWC Hall of Impact
Previous Speakers Include
Nobel laureates, technology founders, regulators, CEOs and scientific pioneers who have taken the PMWC stage.
